- Home
- MRCC vs ABOS Comparison
MRCC vs ABOS Comparison
Compare MRCC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- ABOS
- Stock Information
- Founded
- MRCC 2011
- ABOS 1996
- Country
- MRCC United States
- ABOS United States
- Employees
- MRCC N/A
- ABOS N/A
- Industry
- MRCC Investment Managers
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- MRCC Finance
- ABOS Health Care
- Exchange
- MRCC Nasdaq
- ABOS Nasdaq
- Market Cap
- MRCC 174.8M
- ABOS 99.1M
- IPO Year
- MRCC 2012
- ABOS 2021
- Fundamental
- Price
- MRCC $8.24
- ABOS $1.56
- Analyst Decision
- MRCC Strong Buy
- ABOS Strong Buy
- Analyst Count
- MRCC 1
- ABOS 3
- Target Price
- MRCC $9.00
- ABOS $9.33
- AVG Volume (30 Days)
- MRCC 65.9K
- ABOS 379.4K
- Earning Date
- MRCC 11-12-2024
- ABOS 11-12-2024
- Dividend Yield
- MRCC 12.14%
- ABOS N/A
- EPS Growth
- MRCC 298.01
- ABOS N/A
- EPS
- MRCC 0.60
- ABOS N/A
- Revenue
- MRCC $62,007,000.00
- ABOS N/A
- Revenue This Year
- MRCC N/A
- ABOS N/A
- Revenue Next Year
- MRCC N/A
- ABOS N/A
- P/E Ratio
- MRCC $13.73
- ABOS N/A
- Revenue Growth
- MRCC N/A
- ABOS N/A
- 52 Week Low
- MRCC $6.97
- ABOS $1.54
- 52 Week High
- MRCC $8.80
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- MRCC 46.26
- ABOS 30.29
- Support Level
- MRCC $8.10
- ABOS $1.69
- Resistance Level
- MRCC $8.80
- ABOS $1.88
- Average True Range (ATR)
- MRCC 0.21
- ABOS 0.13
- MACD
- MRCC -0.02
- ABOS -0.00
- Stochastic Oscillator
- MRCC 23.29
- ABOS 4.88
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.